论文部分内容阅读
用放射免疫法测定７５例原发性肺癌、３２例肺良性疾病患者和３２名健康人血浆心钠素（ＡＮＰ）含量，并比较２０例肺癌患者治疗前后血浆ＡＮＰ含量变化。结果表明，血浆ＡＮＰ肺癌组显著高于肺良性疾病组和健康组（Ｐ＜０．０１）；小细胞肺癌（ＳＣＬＣ）显著高于鳞癌和腺癌（Ｐ＜０．０１）；各期肺癌之间差异光显著性（Ｐ＞０．０５）；ＡＮＰ对肺癌的阳性检出率为４６．６７％；治疗后血浆ＡＮＰ显著低于治疗前（Ｐ＜０．００１）；放、化疗后ＳＣＬＣＡＮＰ下降程度显著高于鳞癌和腺癌（Ｐ＜０．０５）。所以，血浆ＡＮＰ的测定有助于肺癌的诊断、组织学分型，也是判断疗效的重要指标。
Radioimmunoassay was used to determine plasma atrial natriuretic peptide (ANP) levels in 75 patients with primary lung cancer, 32 patients with benign lung disease, and 32 healthy individuals. Changes in plasma ANP levels before and after treatment were compared in 20 patients with lung cancer. The results showed that plasma ANP lung cancer group was significantly higher than benign lung disease group and healthy group (P <0.01); small cell lung cancer (SCLC) was significantly higher than squamous cell carcinoma and adenocarcinoma (P <0.01); each stage of lung cancer The difference was significant (P>0.05); the positive rate of ANP in lung cancer was 46.67%; plasma ANP was significantly lower than before treatment (P<0.001); SCLCANP after radiotherapy and chemotherapy The degree of decline was significantly higher than that of squamous cell carcinoma and adenocarcinoma (P < 0.05). Therefore, the determination of plasma ANP contributes to the diagnosis and histological typing of lung cancer, and it is also an important indicator of efficacy.